B-cell chronic lymphocytic leukemia (B-CLL) is the commonest leukemia occurring in Western countries, and arises predominantly in older age groups. Intravenous fludarabine phosphate offers the possibility of a prolonged progression-free interval, an increased response rate and a trend toward better tolerability in comparison with standard polychemotherapy regimens. A more convenient oral formulation of fludarabine phosphate, has been developed. We undertook a literature review that has demonstrated that oral fludarabine phosphate has a similar clinical efficacy and safety profile to the IV formulation and does not adversely affect quality of life. Also we performed a retrospective analysis of patients receiving IV fludarabine for (B-CLL) at our institution to determine the management and resource use of these patients. A cost minimization analysis was then conducted. The per patient costs for the treatment of drug-related adverse events were in local currence R$ 1.476,87 for oral fludarabine and R$ 2.119,64 for IV fludarabine. When costs of a full course of each treatment were compared, the costs per patient for oral fludarabine and IV fludarabine were R$ 22.152,43 and R$ 23.160,31 respectively. In this preliminary analysis, considering that oral fludarabine has a similar efficacy rate and tolerability profile to IV fludarabine, the oral formulation appeared to have a lower total cost per patient. These data require confirmation with formal assessment of cost-effectiveness.

No abstract

The Stroke might cause alterations in movement control due to the sequels of this process. Objective: Analyze the speed-accuracy trade-off of upper limb movement in individuals with sequels of Stroke through a computer software. Method: It is about a cross-sectional study, the sample was composed of 46 individuals divided into two groups: individuals post-stroke, between the ages of 35  and 83 years old, in which 10 were women and 14 were men; and 22 healthy controls aligned by age and sex, in which 8 were women and 14 were men, evaluated through the instruments: Mini mental state examination, Orpington prognostic scale, Fugl-Meyer Assessment Scale, dynamometer, box of blocks and throught the software “Fitts Reciprocal Aiming Task v.2.0. (Horizontal)”, that seeks to understand the motor control of the upper limb, verifying the speed and accuracy of movement through a computer task. Results: The individuals with sequels of Stroke showed a loss in the strength of the palmar grip and manual function. Besides, they showed a longer time in movement in all index of difficulty compared to Control group. However, they showed a similar behaviour to the healthy individuals throughout the execution of the index of difficulty. Conclusion: Thus, it can be concluded that the individuals with sequels of Stroke showed a deficit of the motor control of the upper limb, compared to the healthy individuals, however, these showed the same behavior, with a bigger deficit in the accuracy of movement.

No abstract